medcelerator · clinician one-pager

First FDA-Approved Gene Therapy for Sanfilippo Syndrome Type A

Fayuvi (rebisufligene etisparvovec-hopf) — one-time IV gene therapy for children with Sanfilippo syndrome type A (MPS IIIA)

FDA Approved · United States · September 18, 2026

Condition: Sanfilippo Syndrome Type A

Who this is for

This is for families of children with Sanfilippo syndrome type A (MPS IIIA) who still have preserved neurodevelopmental function and may be candidates for labelled US Fayuvi one-time IV gene therapy at a Qualified Treatment Center — after anti-AAV9 antibody testing and liver / blood work. It explains the first FDA-approved therapy for this disease, the Bayley cognitive results versus natural history, steroid and safety monitoring, UltraCare Gene Therapy Guides, and how to talk with a metabolic genetics team — without treating this as a cure guarantee, dosing if AAV9 antibodies are high, a DIY import as a plan, or “approved” as funded. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/media/194920/download

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/fayuvi-rebisufligene-etisparvovec